Leinco Technologies and CellCarta have announced a strategic collaboration to advance proteomics solutions aimed at accelerating the development of immuno-oncology and other targeted therapies.

The partnership combines Leinco’s portfolio of high-quality, validated antibodies—particularly for applications such as Immunohistochemistry and emerging spatial biology platforms—with CellCarta’s catalogue of Clinical Proteomic Tumor Analysis Consortium-validated antibodies used in its Immuno-MRM assays.

This integration is designed to provide researchers and clinicians with comprehensive tools for biomarker discovery and clinical research.

CellCarta’s Immuno-MRM assays enable highly multiplexed and quantitative measurement of proteins, allowing precise analysis of target expression in clinical samples. These assays rely on antibodies validated to stringent CPTAC standards and are designed to support applications ranging from exploratory research to clinical trials. Integrating these capabilities with Leinco’s validated antibody portfolio is expected to enhance the sensitivity and specificity of proteomic analyses, supporting the development of targeted therapies and personalized medicine approaches.

The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use. Researchers can access smaller antibody panels for exploratory studies, while clinical laboratories can utilize larger volumes for routine testing, ensuring scalability from early discovery to clinical implementation.

By enabling precise and reproducible protein measurements, the collaboration aims to support biomarker discovery, evaluation of therapeutic targets, and monitoring of treatment responses. The integrated proteomics platform is expected to accelerate drug development and contribute to improved outcomes in immuno-oncology and other therapeutic areas.